Respiratory Virus Vaccines Market
Respiratory Virus Vaccines Market Analysis by Inactivated/Killed, Live-attenuated, and Recombinant for Influenza, Measles, Mumps, & Rubella, and Coronavirus Disease (COVID-19) from 2023 to 2033
Analysis of Respiratory Virus Vaccines Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Respiratory Virus Vaccines Market Outlook (2023 to 2033)
The global respiratory virus vaccines market size is valued at US$ 8.69 billion in 2023 and is predicted to reach US$ 18.6 billion by 2033-end, expanding at a CAGR of 7.9% over the forecast period (2023 to 2033).
Respiratory vaccinations, particularly those targeting influenza and pneumonia, are critical in reducing the strain on healthcare systems and lowering the likelihood of COVID-19 co-infection. Healthcare practitioners have been focusing on vaccination to protect people against respiratory diseases such as influenza to reduce outbreaks.
Demand for respiratory virus vaccines has grown significantly in recent years, owing to advancements in vaccine technology, notably the discovery of vaccinations targeting SARS-CoV-2. The effective creation, licensing, and deployment of COVID-19 vaccines highlighted the scientific community's ability to respond quickly to respiratory risks, paving the path for future advances in respiratory vaccine research and development.
Government support and surveillance at both domestic and global levels to monitor the availability, diffusion, and application of influenza vaccinations is a key element driving market expansion. Furthermore, rising investments by notable key companies, with a focus on the introduction of innovative vaccines into the market, have contributed to the industry's growth.
- Pfizer, for example, announced its plans to begin Phase 3 clinical trials for its mRNA-based influenza vaccine in September 2022. This experiment included 25,000 people aged 18 and up from the United States.
| Report Attributes | Details |
|---|---|
|
Respiratory Virus Vaccines Market Size (2022) |
US$ 8.05 Billion |
|
Estimated Market Value (2023) |
US$ 8.69 Billion |
|
Forecasted Market Value (2033) |
US$ 18.6 Billion |
|
Global Market Growth Rate (2023 to 2033) |
7.9% CAGR |
|
Leading Regional Market |
North America |
|
Key Companies Profiled |
|
Don't Need a Global Report?
save 40%! on Country & Region specific reports
What are the Aspects Driving the Expansion of the Respiratory Virus Vaccines Market?
“Increasing Incidence of Viral Respiratory Infections and Rising Awareness of Benefits of Vaccination”
Respiratory viruses are highly contagious and can cause significant morbidity and mortality. Need for effective vaccines to prevent infections and reduce disease burden is a driving factor for respiratory virus vaccines market growth.
The emergence of novel respiratory viruses, such as SARS-CoV-2, has highlighted the importance of robust vaccine development and distribution capabilities. Governments and healthcare organizations are investing in vaccine research and development to be better prepared for future outbreaks.
Public awareness about the importance of vaccination has grown, leading to increased sales of respiratory virus vaccines. Governments and healthcare organizations are implementing vaccine management solutions to achieve wider population coverage.
“Advancements in Vaccine Technology and Increasing Government Investments”
Advancements in vaccine technology, such as mRNA-based vaccines (e.g., Pfizer-BioNTech and Moderna COVID-19 vaccines), have improved the speed and efficiency of vaccine development. This has positively impacted the market by accelerating the availability of vaccines.
Governments worldwide are providing financial support and regulatory incentives to expedite vaccine development and ensure widespread access. Such initiatives have fostered market growth by encouraging research and production.
The respiratory virus vaccines market is highly competitive, with several pharmaceutical companies, biotechnology firms, and research institutions actively involved in vaccine development. Collaborations between public and private entities to leverage expertise and resources are common.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
What are the Hurdles That Manufacturers of Respiratory Virus Vaccines Need to Navigate?
“Vaccine Hesitancy and Stringent Regulations Governing Vaccine Approvals”
Vaccine hesitancy, characterized by doubts, concerns, or reluctance about vaccines, poses a significant challenge. Misinformation, lack of trust in healthcare systems, and fear of side effects can hinder vaccine uptake, impacting the market's growth and effectiveness in preventing respiratory viral infections.
Developing and gaining regulatory approval for vaccines is a complex and time-consuming process. Stringent regulatory requirements and extensive clinical trials can delay vaccine development and market entry.
“Complex and Resource-Intensive Vaccine Manufacturing Processes”
Vaccines can be costly to develop, manufacture, and distribute. Pricing strategies, reimbursement policies, and affordability challenges can affect the market dynamics and accessibility of respiratory virus vaccines, especially in regions with limited healthcare resources.
Scaling up vaccine production to meet global demand can be a significant restraint. Vaccine manufacturing processes can be complex and resource-intensive, and expanding production capacity requires significant investments in facilities, equipment, and skilled personnel.
Country-wise Insights
What are the Prospects for the Growth of the Respiratory Virus Vaccines in the United States?
“Extensive Vaccination Campaigns, Robust Healthcare Infrastructure, and Government Funding”
The United States offers vaccines targeting respiratory viruses such as influenza, respiratory syncytial viruses (RSVs), and coronaviruses (including SARS-CoV-2).
The COVID-19 pandemic has had a substantial impact on market growth in the United States. Development and distribution of COVID-19 vaccines have been a primary focus, with several vaccines authorized for emergency use, including those developed by Pfizer-BioNTech, Moderna, Johnson & Johnson, and AstraZeneca. The government has launched extensive vaccination campaigns, aiming for high population coverage.
The United States has a robust vaccination infrastructure comprising healthcare providers, public health agencies, pharmacies, and vaccination centers. These entities play a crucial role in administering respiratory virus vaccines, particularly during mass vaccination campaigns.
The government plays a vital role in supporting vaccine development and distribution. Initiatives such as Operation Warp Speed, which accelerated the development of COVID-19 vaccines, and funding through agencies such as the National Institutes of Health (NIH) and the Biomedical Advanced Research and Development Authority (BARDA), have facilitated research and production efforts.
Why is Demand for Respiratory Virus Vaccines Growing in China?
“Robust Vaccine Manufacturing Capacity and Increasing Public Awareness about Benefits of Vaccination”
The respiratory virus vaccines market in China is expanding due to the growth of the pharmaceutical and healthcare industries. This can be ascribed to the country's well-functioning research laboratories. In addition, the prevalence of respiratory diseases is increasing, with a huge number of firms seeking to produce a vaccine against disorders such as COVID-19.
China has a robust vaccine manufacturing capacity. It is one of the largest vaccine producers globally and has invested heavily in vaccine manufacturing infrastructure. This capacity has allowed China to meet its domestic demand for respiratory virus vaccines and contribute to global vaccine sales.
Public awareness and acceptance of vaccines have been increasing in China in recent years. Government-led education campaigns, healthcare provider recommendations, and the influence of social media platforms have played a role in raising awareness about the importance of vaccination.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Category-wise Insights
Which Type of Respiratory Virus Vaccine Accounts for High Sales?
“Safety and Efficacy of Inactive/Killed Respiratory Virus Vaccines Boosting Their Sales”
Inactive or killed respiratory virus vaccines, also known as inactivated vaccines, are a type of vaccine that contains viruses that have been rendered non-infectious but retain their ability to stimulate an immune response. These vaccines are used to prevent viral respiratory infections by providing immunity against specific viruses.
These vaccines are generally considered safe and have a long history of successful use. Since the viruses in these vaccines are inactivated, there is no risk of causing the disease they target. However, they may be less effective in stimulating a strong and long-lasting immune response than live attenuated vaccines or newer vaccine technologies. Booster doses or periodic revaccination may be required to maintain immunity.
Inactivated vaccines have played a crucial role in preventing respiratory viral infections and have been widely used for many years. However, it is worth noting that newer vaccine technologies, such as mRNA-based vaccines, have gained prominence in recent years, particularly in the context of the COVID-19 pandemic. These newer technologies offer advantages such as faster development timelines and potentially enhanced immune responses.
Which Medical Condition is Respiratory Virus Vaccines Extensively Utilized For?
“Rising Global Campaigns and Collaborations between WHO and Healthcare Agencies Driving Widespread Adoption of Influenza Respiratory Virus Vaccines”
The influenza respiratory virus vaccine, commonly known as the flu vaccine, is specifically designed to protect against influenza viruses. Influenza is a contagious respiratory illness caused by influenza viruses, and the flu vaccine is an essential tool in preventing flu infections.
Campaigns are conducted worldwide to promote widespread flu vaccination and reduce the impact of seasonal influenza. National health authorities, healthcare providers, and public health organizations collaborate to raise awareness and improve vaccine coverage.
The influenza vaccine is updated annually to account for the most prevalent circulating strains. The World Health Organization (WHO) and the United States Centers for Disease Control and Prevention (CDC) collaborate to determine the specific strains to include in each year's vaccine based on global surveillance data.
Effectiveness of the influenza vaccine can vary from year to year due to the circulating strains and how well the vaccine matches them. The vaccine's effectiveness also depends on individual factors such as age, overall health, and immune response. However, even if the vaccine's effectiveness is moderate, it can still significantly reduce the risk of severe illness, hospitalization, and death from influenza.
Competitive Landscape
The respiratory virus vaccines market is influenced by factors such as research and development capabilities, manufacturing capacities, regulatory compliance, vaccine efficacy and safety profiles, supply chain capabilities, pricing strategies, and distribution networks. Government contracts, public health partnerships, and collaborations with research institutions also play a role in shaping the competitive dynamics within the market.
- AstraZeneca and the University of Oxford entered into a collaboration in April 2020 to develop a vaccine for COVID-19.
- In April 2020, Serum Institute of India Pvt. Ltd. announced a collaboration with the University of Oxford to speed up the development of a COVID-19 vaccine developed by the university.
Key Segments of Respiratory Virus Vaccine Industry Research
-
By Type :
- Inactivated/Killed
- Live-attenuated
- Recombinant
-
By Route of Administration :
- Intramuscular
- Intranasal
- Subcutaneous
-
By Indication :
- Influenza
- Measles
- Mumps & Rubella
- Coronavirus Disease (COVID-19)
-
By Age Group :
- Pediatric
- Adults
-
By End User :
- Physician Offices
- Hospitals
- Clinics
- Pharmacies/Stores
-
By Region :
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
Table of Content
1. Executive Summary 1.1. Summary of Key Findings 1.2. Summary of Statistics 1.3. Fact.MR Analysis and Recommendations 2. Market Overview 2.1. Market Introduction 2.2. Market Definition 2.3. Market Taxonomy 3. Market Risks & Trends Assessment 3.1. COVID-19 Impact Benchmark with Previous Crisis 3.1.1. Change in Demand and Consumption Growth 3.1.2. Before and After COVID-19 Crisis (Projected) 3.1.3. Before and after SARS Pandemic (Actual) 3.1.4. Before and After Sub-prime Crisis – 2008 (Actual) 3.1.5. Change in Demand post Recovery Period (After Each Crisis) 3.2. Impact on Market Value (US$ Mn) 3.2.1. Likely Loss of Value in 2022 3.2.2. Mid-term and Long Term Forecast 3.2.3. Quarter by Quarter Dip and Recovery Assessment 3.3. Anticipated Demand and Value Recovery Curve 3.3.1. Likelihood of U-Shape Recovery 3.3.2. Likelihood of L-Shape Recovery 3.4. Recovery Period Assessment by Key Countries 4. Market Background and Associated Industry Indicators 4.1. Global Pharmaceutical Industry Outlook 4.1.1. Key Trends in Pharmaceutical Market 4.1.2. Pharmaceutical Market, by Region 4.1.3. Pharmaceutical Market, by Competition 4.2. Global Healthcare Industry Outlook 4.2.1. Key trends in Healthcare Industry 4.3. Healthcare Industry, by Region 4.4. Forecast Factors - Relevance & Impact for Respiratory Virus Vaccines 4.4.1. Key Market Players Historic Growth 4.4.2. Pharmaceutical Industry Growth Outlook 4.4.3. Others 4.5. Value Chain Analysis and Operating Margins 4.5.1. List of Raw Material Suppliers 4.5.2. List of Key Manufacturers 4.5.3. List of End-users 4.5.4. Profit Margins 4.5.5. Notes on Value Added at Each Node in the Value Chain 4.6. Market Dynamics 4.6.1. Drivers 4.6.2. Restraints and Market Risks 4.6.3. Opportunity Analysis 5. Global Market Demand Analysis 2018-2022 and Forecast, 2023-2033 5.1. Historical Market Analysis, 2018-2022 5.2. Current and Future Market Projections, 2023-2033 5.2.1. Y-o-Y Growth Trend Analysis 5.2.2. Absolute $ Opportunity Analysis 6. Global Market - Pricing Analysis 6.1. Regional Pricing Analysis 6.2. Pricing Break-up 6.3. Global Average Pricing Analysis Benchmark 7. Global Market Demand (in US$ Mn) Analysis 2018-2022 and Forecast, 2023-2033 7.1. Historical Market Value (US$ Mn) Analysis, 2018-2022 7.2. Current and Future Market Value (US$ Mn) Projections, 2023-2033 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Type 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Mn) and Analysis by Type, 2018-2022 8.3. Current and Future Market Size (US$ Mn) and Analysis and Forecast by Type, 2023-2033 8.3.1. Inactivated/Killed Vaccines 8.3.2. Live-attenuated Vaccines 8.3.3. Recombinant Vaccines 8.4. Market Attractiveness Analysis by Type 9. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Route of Administration 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Mn) and Analysis by Route of Administration, 2018-2022 9.3. Current and Future Market Size (US$ Mn) and Analysis and Forecast by Route of Administration, 2023-2033 9.3.1. Intramuscular 9.3.2. Intranasal 9.3.3. Subcutaneous 10. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Indication 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Mn) and Analysis by Route of Administration, 2018-2022 10.3. Current and Future Market Size (US$ Mn) and Analysis and Forecast by Indication, 2023-2033 10.3.1. Influenza 10.3.2. Measles, Mumps & Rubella 10.3.3. Coronavirus Disease (COVID-19) 11. Global Market Value (US$ Mn) Forecast, by Age Group 11.1. Global Market Value Forecast, by Age Group, 2023-2033 11.1.1. Pediatric 11.1.2. Adults 12. Global Market Attractiveness Analysis, by Age Group 13. Global Market Analysis 2018-2022 and Forecast 2023-2033, By End user 13.1. Introduction / Key Findings 13.2. Historical Market Size (US$ Mn) and Analysis by End-user, 2018-2022 13.3. Current and Future Market Size (US$ Mn) and Analysis and Forecast by End-user, 2023-2033 13.3.1. Physician’s Office 13.3.2. Hospitals 13.3.3. Clinics 13.3.4. Pharmacies/Stores 14. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Region 14.1. Introduction / Key Findings 14.2. Historical Market Size (US$ Mn) Analysis By Region, 2018-2022 14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2023-2033 14.3.1. North America 14.3.2. Latin America 14.3.3. Europe 14.3.4. Asia Pacific 14.3.5. Middle East & Africa 15. North America Market Analysis 2018-2022 and Forecast 2023-2033 15.1. Introduction 15.2. Pricing Analysis 15.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022 15.4. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023-2033 15.4.1. By Country 15.4.2. U.S. 15.4.3. Canada 15.4.4. By Type 15.4.5. By Route of Administration 15.4.6. By Indication 15.4.7. By Age Group 15.4.8. By End User 15.5. Market Attractiveness Analysis 15.5.1. By Country 15.5.2. By Type 15.5.3. By Route of Administration 15.5.4. By Indication 15.5.5. By Age Group 15.5.6. By End User 15.6. Market Trends 15.7. Key Market Participants - Intensity Mapping 15.8. Drivers and Restraints - Impact Analysis 16. Latin America Market Analysis 2018-2022 and Forecast 2023-2033 16.1. Introduction 16.2. Pricing Analysis 16.3. Historical Market Size (US$ Mn) and Trend Analysis by Market Taxonomy, 2018-2022 16.4. Market Size (US$ Mn) and Forecast By Market Taxonomy, 2023-2033 16.4.1. By Country 16.4.2. Brazil 16.4.3. Mexico 16.4.4. Rest of Latin America 16.4.5. By Type 16.4.6. By Route of Administration 16.4.7. By Indication 16.4.8. By Age Group 16.4.9. By End-user 16.5. Market Attractiveness Analysis 16.5.1. By Country 16.5.2. By Type 16.5.3. By Route of Administration 16.5.4. By Indication 16.5.5. By Age Group 16.5.6. By End-user 16.6. Market Trends 16.7. Key Market Participants - Intensity Mapping 16.8. Drivers and Restraints - Impact Analysis 17. Europe Market Analysis 2018-2022 and Forecast 2023-2033 17.1. Introduction 17.2. Pricing Analysis 17.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022 17.4. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023-2033 17.4.1. By Country 17.4.2. Germany 17.4.3. Italy 17.4.4. France 17.4.5. U.K. 17.4.6. Spain 17.4.7. Russia 17.4.8. Poland 17.4.9. Rest of Europe 17.4.10. By Type 17.4.11. By Route of Administration 17.4.12. By Indication 17.4.13. By Age Group 17.4.14. By End-user 17.5. Market Attractiveness Analysis 17.5.1. By Country 17.5.2. By Type 17.5.3. By Route of Administration 17.5.4. By Indication 17.5.5. By Age Group 17.5.6. By End-user 17.6. Market Trends 17.7. Key Market Participants - Intensity Mapping 17.8. Drivers and Restraints - Impact Analysis 18. Asia Pacific Market Analysis 2018-2022 and Forecast 2023-2033 18.1. Introduction 18.2. Pricing Analysis 18.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022 18.4. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023-2033 18.4.1. By Country 18.4.2. China 18.4.3. South Korea 18.4.4. By Type 18.4.5. By Route of Administration 18.4.6. By Indication 18.4.7. By Age Group 18.4.8. By End-user 18.5. Market Attractiveness Analysis 18.5.1. By Country 18.5.2. By Type 18.5.3. By Route of Administration 18.5.4. By Indication 18.5.5. By Age Group 18.5.6. By End-user 18.6. Market Trends 18.7. Key Market Participants - Intensity Mapping 18.8. Drivers and Restraints - Impact Analysis 19. Middle East and Africa Market Analysis 2018-2022 and Forecast 2023-2033 19.1. Introduction 19.2. Pricing Analysis 19.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022 19.4. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023-2033 19.4.1. By Country 19.4.2. GCC Countries 19.4.3. Israel 19.4.4. South Africa 19.4.5. Rest of Middle East and Africa 19.4.6. By Country 19.4.7. By Type 19.4.8. By Route of Administration 19.4.9. By Indication 19.4.10. By Age Group 19.4.11. By End-user 19.5. Market Attractiveness Analysis 19.5.1. By Country 19.5.2. By Type 19.5.3. By Route of Administration 19.5.4. By Indication 19.5.5. By Age Group 19.5.6. By End-user 19.6. Market Trends 19.7. Key Market Participants - Intensity Mapping 19.8. Drivers and Restraints - Impact Analysis 20. Key Countries Market Analysis 2018-2022 and Forecast 2023-2033 20.1. Introduction 20.1.1. Market Value Proportion Analysis, By Key Countries 20.1.2. Global Vs. Country Growth Comparison 20.2. U.S. Market Analysis 20.2.1. Pricing Analysis 20.2.2. Market Value Proportion Analysis by Market Taxonomy 20.2.3. Market Value (US$ Mn) Analysis and Forecast by Market Taxonomy 20.2.4. By Type 20.2.5. By Route of Administration 20.2.6. By Indication 20.2.7. By Age Group 20.2.8. By End-user 20.3. Canada Market Analysis 20.3.1. Pricing Analysis 20.3.2. Market Value Proportion Analysis by Market Taxonomy 20.3.3. Market Value (US$ Mn) Analysis and Forecast by Market Taxonomy 20.3.4. By Type 20.3.5. By Route of Administration 20.3.6. By Indication 20.3.7. By Age Group 20.3.8. By End-user 20.4. Germany Market Analysis 20.4.1. Pricing Analysis 20.4.2. Market Value Proportion Analysis by Market Taxonomy 20.4.3. Market Value (US$ Mn) Analysis and Forecast by Market Taxonomy 20.4.4. By Type 20.4.5. By Route of Administration 20.4.6. By Indication 20.4.7. By Age Group 20.4.8. By End-user 20.5. France Market Analysis 20.5.1. Pricing Analysis 20.5.2. Market Value Proportion Analysis by Market Taxonomy 20.5.3. Market Value (US$ Mn) Analysis and Forecast by Market Taxonomy 20.5.4. By Type 20.5.5. By Route of Administration 20.5.6. By Indication 20.5.7. By Age Group 20.5.8. By End-user 20.6. UK Market Analysis 20.6.1. Pricing Analysis 20.6.2. Market Value Proportion Analysis by Market Taxonomy 20.6.3. Market Value (US$ Mn) Analysis and Forecast by Market Taxonomy 20.6.4. By Type 20.6.5. By Route of Administration 20.6.6. By Indication 20.6.7. By Age Group 20.6.8. By End-user 20.6.9. BENELUX Market Analysis 20.6.10. Pricing Analysis 20.6.11. Market Value Proportion Analysis by Market Taxonomy 20.6.12. Market Value (US$ Mn) Analysis and Forecast by Market Taxonomy 20.6.13. By Type 20.6.14. By Route of Administration 20.6.15. By Indication 20.6.16. By Age Group 20.6.17. By End-user 20.6.18. Russia Market Analysis 20.6.19. Pricing Analysis 20.6.20. Market Value Proportion Analysis by Market Taxonomy 20.6.21. Market Value (US$ Mn) Analysis and Forecast by Market Taxonomy 20.6.22. By Type 20.6.23. By Route of Administration 20.6.24. By Indication 20.6.25. By Age Group 20.6.26. By End-user 20.6.27. India Market Analysis 20.6.28. Pricing Analysis 20.6.29. Market Value Proportion Analysis by Market Taxonomy 20.6.30. Market Value (US$ Mn) Analysis and Forecast by Market Taxonomy 20.6.31. By Type 20.6.32. By Route of Administration 20.6.33. By Indication 20.6.34. By Age Group 20.6.35. By End-user 20.6.36. Malaysia Market Analysis 20.6.37. Pricing Analysis 20.6.38. Market Value Proportion Analysis by Market Taxonomy 20.6.39. Market Value (US$ Mn) Analysis and Forecast by Market Taxonomy 20.6.40. By Type 20.6.41. By Route of Administration 20.6.42. By Indication 20.6.43. By Age Group 20.6.44. By End-user 20.6.45. China Market Analysis 20.6.46. Pricing Analysis 20.6.47. Market Value Proportion Analysis by Market Taxonomy 20.6.48. Market Value (US$ Mn) and Analysis and Forecast by Market Taxonomy 20.6.49. By Type 20.6.50. By Route of Administration 20.6.51. By Indication 20.6.52. By Age Group 20.6.53. By End-user 20.6.54. Poland Market Analysis 20.6.55. Pricing Analysis 20.6.56. Market Value Proportion Analysis by Market Taxonomy 20.6.57. Market Value (US$ Mn) and Analysis and Forecast by Market Taxonomy 20.6.58. By Type 20.6.59. By Route of Administration 20.6.60. By Indication 20.6.61. By Age Group 20.6.62. By End-user 20.6.63. South Korea Market Analysis 20.6.64. Pricing Analysis 20.6.65. Market Value Proportion Analysis by Market Taxonomy 20.6.66. Market Value (US$ Mn) and Analysis and Forecast by Market Taxonomy 20.6.67. By Type 20.6.68. By Route of Administration 20.6.69. By Indication 20.6.70. By Age Group 20.6.71. By End-user 21. Market Structure Analysis 21.1. Market Analysis by Tier of Companies (Respiratory Virus Vaccines) 21.2. Market Concentration 21.3. Market Share Analysis of Top Players 22. Competition Analysis 22.1. Competition Dashboard 22.2. Competition Benchmarking 22.3. Competition Deep Dive 22.3.1. CSL Limited 22.3.1.1. Overview 22.3.1.2. Product Portfolio 22.3.1.3. Profitability by Market Segments (Product/Region) 22.3.1.4. Sales Footprint 22.3.1.5. Strategy Overview 22.3.2. Sanofi 22.3.2.1. Overview 22.3.2.2. Product Portfolio 22.3.2.3. Profitability by Market Segments (Product/Region) 22.3.2.4. Sales Footprint 22.3.2.5. Strategy Overview 22.3.3. AstraZeneca 22.3.3.1. Overview 22.3.3.2. Product Portfolio 22.3.3.3. Profitability by Market Segments (Product/Region) 22.3.3.4. Sales Footprint 22.3.3.5. Strategy Overview 22.3.4. Merck & Co., Inc. 22.3.4.1. Overview 22.3.4.2. Product Portfolio 22.3.4.3. Profitability by Market Segments (Product/Region) 22.3.4.4. Sales Footprint 22.3.4.5. Strategy Overview 22.3.5. GlaxoSmithKline plc 22.3.5.1. Overview 22.3.5.2. Product Portfolio 22.3.5.3. Profitability by Market Segments (Product/Region) 22.3.5.4. Sales Footprint 22.3.5.5. Strategy Overview 22.3.6. Serum Institute of India Pvt. Ltd. 22.3.6.1. Overview 22.3.6.2. Product Portfolio 22.3.6.3. Profitability by Market Segments (Product/Region) 22.3.6.4. Sales Footprint 22.3.6.5. Strategy Overview 22.3.7. Bharat Biotech 22.3.7.1. Overview 22.3.7.2. Product Portfolio 22.3.7.3. Profitability by Market Segments (Product/Region) 22.3.7.4. Sales Footprint 22.3.7.5. Strategy Overview 22.3.8. Sinovac Biotech Ltd. 22.3.8.1. Overview 22.3.8.2. Product Portfolio 22.3.8.3. Profitability by Market Segments (Product/Region) 22.3.8.4. Sales Footprint 22.3.8.5. Strategy Overview 23. Assumptions and Acronyms Used 24. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Pipeline Analysis (1/4)
Table 02: Pipeline Analysis (2/4)
Table 03: Pipeline Analysis (3/4)
Table 04: Pipeline Analysis (4/4)
Table 05: Key Industry Events (Mergers, Acquisitions, Collaborations, Approvals, etc.) (1/3)
Table 06: Key Industry Events (Mergers, Acquisitions, Collaborations, Approvals, etc.) (2/3)
Table 07: Key Industry Events (Mergers, Acquisitions, Collaborations, Approvals, etc.) (3/3)
Table 08: Global Market Value (US$ Mn) Forecast, by Type, 2023-2033
Table 09: Global Market Value (US$ Mn) Forecast, by Route of Administration, 2023-2033
Table 10: Global Market Value (US$ Mn) Forecast, by Indication, 2023-2033
Table 11: Global Market Value (US$ Mn) Forecast, by Age Group, 2023-2033
Table 12: Global Market Value (US$ Mn) Forecast, by End-user, 2023-2033
Table 13: Global Market Value (US$ Mn) Forecast, by Region, 2023-2033
Table 14: North America Market Value (US$ Mn) Forecast, by Country, 2023-2033
Table 15: North America Market Value (US$ Mn) Forecast, by Type, 2023-2033
Table 16: North America Market Value (US$ Mn) Forecast, by Route of Administration, 2023-2033
Table 17: North America Market Value (US$ Mn) Forecast, by Indication, 2023-2033
Table 18: North America Market Value (US$ Mn) Forecast, by Age Group, 2023-2033
Table 19: North America Market Value (US$ Mn) Forecast, by End-user, 2023-2033
Table 20: Europe Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023-2033
Table 21: Europe Market Value (US$ Mn) Forecast, by Type, 2023-2033
Table 22: Europe Market Value (US$ Mn) Forecast, by Route of Administration, 2023-2033
Table 23: Europe Market Value (US$ Mn) Forecast, by Indication, 2023-2033
Table 24: Europe Market Value (US$ Mn) Forecast, by Age Group, 2023-2033
Table 25: Europe Market Value (US$ Mn) Forecast, by End-user, 2023-2033
Table 26: Asia Pacific Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023-2033
Table 27: Asia Pacific Market Value (US$ Mn) Forecast, by Type, 2023-2033
Table 28: Asia Pacific Market Value (US$ Mn) Forecast, by Route of Administration, 2023-2033
Table 29: Asia Pacific Market Value (US$ Mn) Forecast, by Indication, 2023-2033
Table 30: Asia Pacific Market Value (US$ Mn) Forecast, by Age Group, 2023-2033
Table 31: Asia Pacific Market Value (US$ Mn) Forecast, by End-user, 2023-2033
Table 32: Latin America Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023-2033
Table 33: Latin America Market Value (US$ Mn) Forecast, by Type, 2023-2033
Table 34: Latin America Market Value (US$ Mn) Forecast, by Route of Administration, 2023-2033
Table 35: Latin America Market Value (US$ Mn) Forecast, by Indication, 2023-2033
Table 36: Latin America Market Value (US$ Mn) Forecast, by Age Group, 2023-2033
Table 37: Latin America Market Value (US$ Mn) Forecast, by End-user, 2023-2033
Table 38: Middle East & Africa Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023-2033
Table 39: Middle East & Africa Market Value (US$ Mn) Forecast, by Type, 2023-2033
Table 40: Middle East & Africa Market Value (US$ Mn) Forecast, by Route of Administration, 2023-2033
Table 41: Middle East & Africa Market Value (US$ Mn) Forecast, by Indication, 2023-2033
Table 42: Middle East & Africa Market Value (US$ Mn) Forecast, by Age Group, 2023-2033
Table 43: Middle East & Africa Market Value (US$ Mn) Forecast, by End-user, 2023-2033
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Value (US$ Mn) Forecast, 2023-2033
Figure 02: Global Market Value Share Analysis, by Type, 2018 and 2022
Figure 03: Global Market Attractiveness Analysis, by Type, 2018-2022
Figure 04: Global Market Value (US$ Mn) and Y-o-Y Growth (%), by Inactivated/Killed Vaccines, 2023-2033
Figure 05: Global Market Value (US$ Mn) and Y-o-Y Growth (%), by Live-attenuated Vaccines, 2023-2033
Figure 06: Global Market Value (US$ Mn) and Y-o-Y Growth (%), by Recombinant vaccines, 2023-2033
Figure 07: Global Market Value Share Analysis, by Route of Administration, 2018 and 2022
Figure 08: Global Market Attractiveness Analysis, by Route of Administration, 2018-2022
Figure 09: Global Market Value (US$ Mn) and Y-o-Y Growth (%), by Intramuscular, 2023-2033
Figure 10: Global Market Value (US$ Mn) and Y-o-Y Growth (%), by Intranasal, 2023-2033
Figure 11: Global Market Value (US$ Mn) and Y-o-Y Growth (%), by Subcutaneous, 2023-2033
Figure 12: Global Market Value Share Analysis, by Indication, 2018 and 2022
Figure 13: Global Market Attractiveness Analysis, by Indication, 2018-2022
Figure 14: Global Market Value (US$ Mn) and Y-o-Y Growth (%), by Influenza, 2023-2033
Figure 15: Global Market Value (US$ Mn) and Y-o-Y Growth (%), by Measles, Mumps & Rubella, 2023-2033
Figure 16: Global Market Value (US$ Mn) and Y-o-Y Growth (%), by Coronavirus Disease (COVID-19), 2023-2033
Figure 17: Global Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2023-2033
Figure 18: Global Market Value Share Analysis, by Age Group, 2018 and 2022
Figure 19: Global Market Attractiveness Analysis, by Age Group, 2018-2022
Figure 20: Global Market Value (US$ Mn) and Y-o-Y Growth (%), by Pediatric, 2023-2033
Figure 21: Global Market Value (US$ Mn) and Y-o-Y Growth (%), by Adult, 2023-2033
Figure 22: Global Market Value Share Analysis, by End-user, 2018 and 2022
Figure 23: Global Market Attractiveness Analysis, by End-user, 2018-2022
Figure 24: Global Market Value (US$ Mn) and Y-o-Y Growth (%), by Physician Offices, 2023-2033
Figure 25: Global Market Value (US$ Mn) and Y-o-Y Growth (%), by Hospitals, 2023-2033
Figure 26: Global Market Value (US$ Mn) and Y-o-Y Growth (%), by Clinics, 2023-2033
Figure 27: Global Market Value (US$ Mn) and Y-o-Y Growth (%), by Pharmacy/Store, 2023-2033
Figure 28: Global Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2023-2033
Figure 29: Global Market Value Share Analysis, by Region, 2018 and 2022
Figure 30: Global Market Attractiveness Analysis, by Region, 2018-2022
Figure 31: North America Market Value (US$ Mn) Forecast, 2023-2033
Figure 32: North America Market Value Share Analysis, by Country, 2018 and 2022
Figure 33: North America Market Attractiveness Analysis, by Country, 2018-2022
Figure 34: North America Market Value Share Analysis, by Type, 2018 and 2022
Figure 35: North America Market Attractiveness Analysis, by Type, 2018-2022
Figure 36: North America Market Value Share Analysis, by Route of Administration, 2018 and 2022
Figure 37: North America Market Attractiveness Analysis, by Route of Administration, 2018-2022
Figure 38: North America Market Value Share Analysis, by Indication, 2018 and 2022
Figure 39: North America Market Attractiveness Analysis, by Indication, 2018-2022
Figure 40: North America Market Value Share Analysis, by Age Group, 2018 and 2022
Figure 41: North America Market Attractiveness Analysis, by Age Group, 2018-2022
Figure 42: North America Market Value Share Analysis, by End-user, 2018 and 2022
Figure 43: North America Market Attractiveness Analysis, by End-user, 2018-2022
Figure 44: Europe Market Value (US$ Mn) Forecast, 2023-2033
Figure 45: Europe Market Value Share Analysis, by Country/Sub-region, 2018 and 2022
Figure 46: Europe Market Attractiveness Analysis, by Country, 2018-2022
Figure 47: Europe Market Value Share Analysis, by Type, 2018 and 2022
Figure 48: Europe Market Attractiveness Analysis, by Type, 2018-2022
Figure 49: Europe Market Value Share Analysis, by Route of Administration, 2018 and 2022
Figure 50: Europe Market Attractiveness Analysis, by Route of Administration, 2018-2022
Figure 51: Europe Market Value Share Analysis, by Indication, 2018 and 2022
Figure 52: Europe Market Attractiveness Analysis, by Indication, 2018-2022
Figure 53: Europe Market Value Share Analysis, by Age Group, 2018 and 2022
Figure 54: Europe Market Attractiveness Analysis, by Age Group, 2018-2022
Figure 55: Europe Market Value Share Analysis, by End-user, 2018 and 2022
Figure 56: Europe Market Attractiveness Analysis, by End-user, 2018-2022
Figure 57: Asia Pacific Market Value (US$ Mn) Forecast, 2023-2033
Figure 58: Asia Pacific Market Value Share Analysis, by Country/Sub-region, 2018 and 2022
Figure 59: Asia Pacific Market Attractiveness Analysis, by Country/Sub-region, 2018-2022
Figure 60: Asia Pacific Market Value Share Analysis, by Type, 2018 and 2022
Figure 61: Asia Pacific Market Attractiveness Analysis, by Type, 2018-2022
Figure 62: Asia Pacific Market Value Share Analysis, by Route of Administration, 2018 and 2022
Figure 63: Asia Pacific Market Attractiveness Analysis, by Route of Administration, 2018-2022
Figure 64: Asia Pacific Market Value Share Analysis, by Indication, 2018 and 2022
Figure 65: Asia Pacific Market Attractiveness Analysis, by Indication, 2018-2022
Figure 66: Asia Pacific Market Value Share Analysis, by Age Group, 2018 and 2022
Figure 67: Asia Pacific Market Attractiveness Analysis, by Age Group, 2018-2022
Figure 68: Asia Pacific Market Value Share Analysis, by End-user, 2018 and 2022
Figure 69: Asia Pacific Market Attractiveness Analysis, by End-user, 2018-2022
Figure 70: Latin America Market Value (US$ Mn) Forecast, 2023-2033
Figure 71: Latin America Market Value Share Analysis, by Country/Sub-region, 2018 and 2022
Figure 72: Latin America Market Attractiveness Analysis, by Country/Sub-region, 2018-2022
Figure 73: Latin America Market Value Share Analysis, by Type, 2018 and 2022
Figure 74: Latin America Market Attractiveness Analysis, by Type, 2018-2022
Figure 75: Latin America Market Value Share Analysis, by Route of Administration, 2018 and 2022
Figure 76: Latin America Market Attractiveness Analysis, by Route of Administration, 2018-2022
Figure 77: Latin America Market Value Share Analysis, by Indication, 2018 and 2022
Figure 78: Latin America Market Attractiveness Analysis, by Indication, 2018-2022
Figure 79: Latin America Market Value Share Analysis, by Age Group, 2018 and 2022
Figure 80: Latin America Market Attractiveness Analysis, by Age Group, 2018-2022
Figure 81: Latin America Market Value Share Analysis, by End-user, 2018 and 2022
Figure 82: Latin America Market Attractiveness Analysis, by End-user, 2018-2022
Figure 83: Middle East & Africa Market Value (US$ Mn) Forecast, 2023-2033
Figure 84: Middle East & Africa Market Value Share Analysis, by Country/Sub-region, 2018 and 2022
Figure 85: Middle East & Africa Market Attractiveness Analysis, by Country/Sub-region, 2018-2022
Figure 86: Middle East & Africa Market Value Share Analysis, by Type, 2018 and 2022
Figure 87: Middle East & Africa Market Attractiveness Analysis, by Type, 2018-2022
Figure 88: Middle East & Africa Market Value Share Analysis, by Route of Administration, 2018 and 2022
Figure 89: Middle East & Africa Market Attractiveness Analysis, by Route of Administration, 2018-2022
Figure 90: Middle East & Africa Market Value Share Analysis, by Indication, 2018 and 2022
Figure 91: Middle East & Africa Market Attractiveness Analysis, by Indication, 2018-2022
Figure 92: Middle East & Africa Market Value Share Analysis, by Age Group, 2018 and 2022
Figure 93: Middle East & Africa Market Attractiveness Analysis, by Age Group, 2018-2022
Figure 94: Middle East & Africa Market Value Share Analysis, by End-user, 2018 and 2022
Figure 95: Middle East & Africa Market Attractiveness Analysis, by End-user, 2018-2022
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What is the current value of the respiratory virus vaccines market?
The global respiratory virus vaccines market is valued at US$ 8.69 billion in 2023.
At what rate are the sales of respiratory virus vaccines predicted to increase?
From 2023 to 2033, sales of respiratory virus vaccines are expected to increase at a CAGR of 7.9%.
What is the projected sales value of respiratory virus vaccines for 2033?
By 2033, worldwide sales of respiratory virus vaccines are forecasted to reach US$ 18.6 billion.
Which country is expected to dominate the global market through 2033?
The United States is expected to hold a leading share of the market in 2033.
Who are the leading suppliers of respiratory virus vaccines?
Sanofi, GlaxoSmithKline plc, and Merck & Co., Inc. are leading manufacturers of respiratory virus vaccines.
Respiratory Virus Vaccines Market